Seminars in Hematology
Volume 43, Issue 1 , Pages 32-41 , January 2006

Prophylaxis and Treatment of Acute Graft-Versus-Host Disease

  • Nelson J. Chao

      Affiliations

    • Corresponding Author InformationAddress correspondence to Nelson J. Chao, MD, Division of Cellular Therapy/BMT, Duke University Medical Center, 2400 Pratt St, Suite 1100, Box 3961, Durham, NC 27705
    • ,
  • Benny J. Chen

References 

  1. Vogelsang GB , Lee L , Bensen-Kennedy DM . Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant . Annu Rev Med . 2003;54:29–52
  2. Socie G , Stone JV , Wingard JR , et al.   Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry . N Engl J Med . 1999;341:14–21
  3. Antin JH , Ferrara JL . Cytokine dysregulation and acute graft-versus-host disease . Blood . 1992;80:2964–2968
  4. Horowitz MM , Gale RP , Sondel PM , et al.   Graft-versus-leukemia reactions after bone marrow transplantation . Blood . 1990;75:555–562
  5. Kolb HJ , Mittermuller J , Clemm C , et al.   Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients . Blood . 1990;76:2462–2465
  6. van Bekkum DW , Roodenburg J , Heidt PJ , van der WD . Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora . J Natl Cancer Inst . 1974;52:401–404
  7. Storb R , Prentice RL , Buckner CD , et al.   Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment . N Engl J Med . 1983;308:302–307
  8. Ferrara JL , Levy R , Chao NJ . Pathophysiologic mechanisms of acute graft-vs.-host disease . Biol Blood Marrow Transplant . 1999;5:347–356
  9. Clift RA , Buckner CD , Appelbaum FR , et al.   Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission (A randomized trial of two irradiation regimens) . Blood . 1990;76:1867–1871
  10. Hill GR , Teshima T , Gerbitz A , et al.   Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia . J Clin Invest . 1999;104:459–467
  11. Johnson BD , Truitt RL . Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease . Blood . 1995;85:3302–3312
  12. Barrett AJ , Mavroudis D , Tisdale J , et al.   T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect . Bone Marrow Transplant . 1998;21:543–551
  13. Holler E , Kolb HJ , Moller A , et al.   Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation . Blood . 1990;75:1011–1016
  14. Shalaby MR , Fendly B , Sheehan KC , Schreiber RD , Ammann AJ . Prevention of the graft-versus-host reaction in newborn mice by antibodies to tumor necrosis factor-alpha . Transplantation . 1989;47:1057–1061
  15. Piguet PF , Grau GE , Allet B , Vassalli P . Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease . J Exp Med . 1987;166:1280–1289
  16. Panoskaltsis-Mortari A , Lacey DL , Vallera DA , Blazar BR . Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice . Blood . 1998;92:3960–3967
  17. Krijanovski OI , Hill GR , Cooke KR , et al.   Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease . Blood . 1999;94:825–831
  18. Bacigalupo A , Lamparelli T , Bruzzi P , et al.   Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors (2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO)) . Blood . 2001;98:2942–2947
  19. Remberger M , Storer B , Ringden O , Anasetti C . Association between pretransplant Thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors . Bone Marrow Transplant . 2002;29:391–397
  20. Basara N , Baurmann H , Kolbe K , et al.   Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia (Results from the multicenter German cooperative study group) . Bone Marrow Transplant . 2005;35:1011–1018
  21. den Haan JM , Sherman NE , Blokland E , et al.   Identification of a graft versus host disease-associated human minor histocompatibility antigen . Science . 1995;268:1476–1480
  22. Goulmy E , Schipper R , Pool J , et al.   Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation . N Engl J Med . 1996;334:281–285
  23. Sette A , Alexander J , Grey HM . Interaction of antigenic peptides with MHC and TCR molecules . Clin Immunol Immunopathol . 1995;76:S168–S171
  24. Yang Y , Wilson JM . CD40 ligand-dependent T cell activation (Requirement of B7-CD28 signaling through CD40) . Science . 1996;273:1862–1864
  25. Green JM , Noel PJ , Sperling AI , et al.   Absence of B7-dependent responses in CD28-deficient mice . Immunity . 1994;1:501–508
  26. Freeman GJ , Gribben JG , Boussiotis VA , et al.   Cloning of B7-2 (A CTLA-4 counter-receptor that costimulates human T cell proliferation) . Science . 1993;262:909–911
  27. Guinan EC , Boussiotis VA , Neuberg D , et al.   Transplantation of anergic histoincompatible bone marrow allografts . N Engl J Med . 1999;340:1704–1714
  28. Vezina C , Kudelski A , Sehgal SN . Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle . J Antibiot (Tokyo) . 1975;28:721–726
  29. Morice WG , Brunn GJ , Wiederrecht G , Siekierka JJ , Abraham RT . Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes . J Biol Chem . 1993;268:3734–3738
  30. Nourse J , Firpo E , Flanagan WM , et al.   Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin . Nature . 1994;372:570–573
  31. Altmeyer A , Dumont FJ . Rapamycin inhibits IL-1-mediated interferon-gamma production in the YAC-1 T cell lymphoma . Cytokine . 1993;5:133–143
  32. Lai JH , Tan TH . CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin . J Biol Chem . 1994;269:30077–30080
  33. Battaglia M , Stabilini A , Roncarolo MG . Rapamycin selectively expands CD4+CD25+FOXP3+ regulatory T cells . Blood . 2005;
  34. Storb R , Epstein RB , Graham TC , Thomas ED . Methotrexate regimens for control of graft-versus-host disease in dogs with allogeneic marrow grafts . Transplantation . 1970;9:240–246
  35. Storb R , Deeg HJ , Whitehead J , et al.   Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia . N Engl J Med . 1986;314:729–735
  36. Ringden O , Klaesson S , Sundberg B , et al.   Decreased incidence of graft-versus-host disease and improved survival with methotrexate combined with cyclosporin compared with monotherapy in recipients of bone marrow from donors other than HLA identical siblings . Bone Marrow Transplant . 1992;9:19–25
  37. Nevill TJ , Tirgan MH , Deeg HJ , et al.   Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation . Bone Marrow Transplant . 1992;9:349–354
  38. Ratanatharathorn V , Nash RA , Przepiorka D , et al.   Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation . Blood . 1998;92:2303–2314
  39. Nash RA , Antin JH , Karanes C , et al.   Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors . Blood . 2000;96:2062–2068
  40. Suthanthiran M , Morris RE , Strom TB . Immunosuppressants (Cellular and molecular mechanisms of action) . Am J Kidney Dis . 1996;28:159–172
  41. Hovi T , Allison AC , Allsop J . Rapid increase of phosphoribosyl pyrophosphate concentration after mitogenic stimulation of lymphocytes . FEBS Lett . 1975;55:291–293
  42. Storb R , Yu C , Wagner JL , et al.   Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation . Blood . 1997;89:3048–3054
  43. Ferrara JL , Deeg HJ . Graft-versus-host disease . N Engl J Med . 1991;324:667–674
  44. Henkart PA , Sitkovsky MV . Cytotoxic lymphocytes. Two ways to kill target cells . Curr Biol . 1994;4:923–925
  45. Mason DW . Subsets of T cells in the rat mediating lethal graft versus-host disease . Transplantation . 1981;32:222–226
  46. Fong TA , Mosmann TR . Alloreactive murine CD8+ T cell clones secrete the Th1 pattern of cytokines . J Immunol . 1990;144:1744–1752
  47. Groux H , Bigler M , de Vries JE , Roncarolo MG . Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells . J Exp Med . 1996;184:19–29
  48. Bensinger WI , Martin PJ , Storer B , et al.   Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers . N Engl J Med . 2001;344:175–181
  49. Mielcarek M , Graf L , Johnson G , Torok-Storb B . Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products (a mechanism for monocyte-mediated suppression of T-cell proliferation) . Blood . 1998;92:215–222
  50. Powles R , Mehta J , Kulkarni S , et al.   Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases (A randomised trial) . Lancet . 2000;355:1231–1237
  51. Yang YG , Dey BR , Sergio JJ , Pearson DA , Sykes M . Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12 . J Clin Invest . 1998;102:2126–2135
  52. Shevach EM , McHugh RS , Piccirillo CA , Thornton AM . Control of T-cell activation by CD4+ CD25+ suppressor T cells . Immunol Rev . 2001;182:58–67
  53. Taylor PA , Lees CJ , Blazar BR . The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality . Blood . 2002;99:3493–3499
  54. Edinger M , Hoffmann P , Ermann J , et al.   CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation . Nat Med . 2003;9:1144–1150
  55. Ghiringhelli F , Larmonier N , Schmitt E , et al.   CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative . Eur J Immunol . 2004;34:336–344
  56. Korngold B , Sprent J . Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow . J Exp Med . 1978;148:1687–1698
  57. Ho VT , Soiffer RJ . The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation . Blood . 2001;98:3192–3204
  58. Truitt RL , Johnson BD . Principles of graft-vs.-leukemia reactivity . Biol Blood Marrow Transplant . 1995;1:61–68
  59. Michalek J , Collins RH , Durrani HP , et al.   Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor beta loci sequences . Proc Natl Acad Sci U S A . 2003;100:1180–1184
  60. Gribben JG , Guinan EC , Boussiotis VA , et al.   Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy (A method to ameliorate graft- versus-host disease and extend the donor pool) . Blood . 1996;87:4887–4893
  61. Blazar BR , Taylor PA , Noelle RJ , Vallera DA . CD4(+) T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses . J Clin Invest . 1998;102:473–482
  62. Zeller JC , Panoskaltsis-Mortari A , Murphy WJ , et al.   Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL- 10 and TGF-beta . J Immunol . 1999;163:3684–3691
  63. Cavazzana-Calvo M , Fromont C , Le Deist F , et al.   Specific elimination of alloreactive T cells by an anti-interleukin-2 receptor B chain-specific immunotoxin . Transplantation . 1990;50:1–7
  64. Solomon SR , Tran T , Carter CS , et al.   Optimized clinical-scale culture conditions for ex vivo selective depletion of host-reactive donor lymphocytes (A strategy for GvHD prophylaxis in allogeneic PBSC transplantation) . Cytotherapy . 2002;4:395–406
  65. Chen BJ , Cui X , Liu C , Chao NJ . Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process . Blood . 2002;99:3083–3088
  66. Guimond M , Balassy A , Barrette M , et al.   P-glycoprotein targeting (a unique strategy to selectively eliminate immunoreactive T cells) . Blood . 2002;100:375–382
  67. Andre-Schmutz I , Le Deist F , Hacein-Bey-Abina S , et al.   Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation (A phase 1/2 study) . Lancet . 2002;360:130–137
  68. Solomon SR , Tran T , Carter CS , et al.   Selective depletion of alloreacting CD25+ cells from stem cell allografts can reduce acute graft-versus-host disease following matched related donor transplantation . Blood . 2004;104:125A
  69. Chen BJ , Cui XY , Sempowski GD , Liu CX , Chao NJ . Transfer of aflogeneic CD62L(-) memory T cells without graft-versus-host disease . Blood . 2004;103:1534–1541
  70. Anderson BE , McNiff J , Yan J , et al.   Memory CD4+ T cells do not induce graft-versus-host disease . J Clin Invest . 2003;112:101–108
  71. Zhang Y , Joe G , Zhu J , et al.   Dendritic cell-activated CD44hiCD8+ T cells are defective in mediating acute graft-versus-host disease but retain graft-versus-leukemia activity . Blood . 2004;103:3970–3978
  72. Xystrakis E , Bernard I , Dejean AS , et al.   Alloreactive CD4 T lymphocytes responsible for acute and chronic graft-versus-host disease are contained within the CD45RChigh but not the CD45RClow subset . Eur J Immunol . 2004;34:408–417
  73. Bonini C , Ferrari G , Verzeletti S , et al.   HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia . Science . 1997;276:1719–1724
  74. Fontaine P , Roy-Proulx G , Knafo L , et al.   Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease . Nat Med . 2001;7:789–794
  75. Ruggeri L , Capanni M , Martelli MF , Velardi A . Cellular therapy (Exploiting NK cell alloreactivity in transplantation) . Curr Opin Hematol . 2001;8:355–359
  76. Ruggeri L , Capanni M , Urbani E , et al.   Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants . Science . 2002;295:2097–2100
  77. Bendelac A , Lantz O , Quimby ME , et al.   CD1 recognition by mouse NK1+ T lymphocytes . Science . 1995;268:863–865
  78. Porcelli SA . The CD1 family (A third lineage of antigen-presenting molecules) . Adv Immunol . 1995;59:1–98
  79. Zeng D , Lewis D , Dejbakhsh-Jones S , et al.   Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease . J Exp Med . 1999;189:1073–1081
  80. Furlong T , Storb R , Anasetti C , et al.   Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities . Bone Marrow Transplant . 2000;26:985–991
  81. Thomas E , Storb R , Clift RA , et al.   Bone-marrow transplantation (first of two parts) . N Engl J Med . 1975;292:832–843
  82. Holler E , Kolb HJ , Wilmanns W . Treatment of GVHD—TNF-antibodies and related antagonists . Bone Marrow Transplant . 1993;12(suppl 3):S29–S31
  83. Ruutu T , Hermans J , van Biezen A , et al.  European Group for Blood and Marrow Transplantation   How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party . Bone Marrow Transplant . 1998;22:614–615
  84. Van Lint MT , Uderzo C , Locasciulli A , et al.   Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone (A multicenter randomized trial from the Italian Group for Bone Marrow Transplantation) . Blood . 1998;92:2288–2293
  85. Martin PJ , Schoch G , Fisher L , et al.   A retrospective analysis of therapy for acute graft-versus-host disease (Initial treatment) . Blood . 1990;76:1464–1472
  86. Weisdorf D , Haake R , Blazar B , et al.   Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation (An analysis of clinical risk features and outcome) . Blood . 1990;75:1024–1030
  87. Hings IM , Filipovich AH , Miller WJ , et al.   Prednisone therapy for acute graft-versus-host disease (Short- versus long-term treatment. A prospective randomized trial) . Transplantation . 1993;56:577–580
  88. Martin PJ , Nelson BJ , Appelbaum FR , et al.   Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation . Blood . 1996;88:824–830
  89. Cahn JY , Bordigoni P , Tiberghien P , et al.   Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study . Transplantation . 1995;60:939–942
  90. Cragg L , Blazar BR , Defor T , et al.   A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease . Biol Blood Marrow Transplant . 2000;6:441–447
  91. Bacigalupo A , Oneto R , Lamparelli T , et al.   Pre-emptive therapy of acute graft-versus-host disease (A pilot study with antithymocyte globulin (ATG)) . Bone Marrow Transplant . 2001;28:1093–1096
  92. Hattori K , Hirano T , Miyajima H , et al.   Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies . Blood . 1998;91:4051–4055
  93. Stuber E , Buschenfeld A , Von Freier A , Arendt T , Folsch UR . Intestinal crypt cell apoptosis in murine acute graft versus host disease is mediated by tumour necrosis factor alpha and not by the FasL-Fas interaction (Effect of pentoxifylline on the development of mucosal atrophy) . Gut . 1999;45:229–235
  94. Daneshpouy M , Socie G , Lemann M , et al.   Activated eosinophils in upper gastrointestinal tract of patients with graft-versus-host disease . Blood . 2002;99:3033–3040
  95. Basara N , Kiehl MG , Blau W , et al.   Mycophenolate Mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients (Four years of experience) . Transplant Proc . 2001;33:2121–2123
  96. Doney KC , Weiden PL , Storb R , Thomas ED . Treatment of graft-versus-host disease in human allogeneic marrow graft recipients (A randomized trial comparing antithymocyte globulin and corticosteroids) . Am J Hematol . 1981;11:1–8
  97. Anasetti C , Martin PJ , Storb R , et al.   Treatment of acute graft-versus-host disease with a nonmitogenic anti-CD3 monoclonal antibody . Transplantation . 1992;54:844–851
  98. Carpenter PA , Appelbaum FR , Corey L , et al.   A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease . Blood . 2002;99:2712–2719
  99. Lee SJ , Zahrieh D , Agura E , et al.   Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease (Results of a randomized trial) . Blood . 2004;104:1559–1564
  100. Deeg HJ , Blazar BR , Bolwell BJ , et al.   Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL . Blood . 2001;98:2052–2058
  101. Ely P , Dunitz J , Rogosheske J , Weisdorf D . Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease . Am J Med . 1991;90:707–710
  102. Grothaus-Pinke B , Gunzelmann S , Fauser AA , Kiehl MG . Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel (Report of an initial experience) . Transplantation . 2001;72:1456–1458
  103. Bertz H , Afting M , Kreisel W , et al.   Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD . Bone Marrow Transplant . 1999;24:1185–1189
  104. McDonald GB , Bouvier M , Hockenbery DM , et al.   Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease (Arandomized, controlled trial) . Gastroenterology . 1998;115:28–35
  105. French LE , Tschopp J . Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease (Potential for therapeutic inhibition) . Schweiz Med Wochenschr . 2000;130:1656–1661
  106. Biedermann BC , Sahner S , Gregor M , et al.   Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease . Lancet . 2002;359:2078–2083

PII: S0037-1963(05)00169-1

doi: 10.1053/j.seminhematol.2005.09.007

Seminars in Hematology
Volume 43, Issue 1 , Pages 32-41 , January 2006

Article Tools

* Image Usage & Resolution